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Abstract
High-throughput sequencing opens avenues to find genetic variations that may be indicative of an increased risk for certain
diseases. Linking these genomic data to other ‘‘omics’’ approaches bears the potential to deepen our understanding of
pathogenic processes at the molecular level. To detect novel single nucleotide polymorphisms (SNPs) for glioblastoma
multiforme (GBM), we used a combination of specific target selection and next generation sequencing (NGS). We generated
a microarray covering the exonic regions of 132 GBM associated genes to enrich target sequences in two GBM tissues and
corresponding leukocytes of the patients. Enriched target genes were sequenced with Illumina and the resulting reads were
mapped to the human genome. With this approach we identified over 6000 SNPs, including over 1300 SNPs located in the
targeted genes. Integrating the genome-wide association study (GWAS) catalog and known disease associated SNPs, we
found that several of the detected SNPs were previously associated with smoking behavior, body mass index, breast cancer
and high-grade glioma. Particularly, the breast cancer associated allele of rs660118 SNP in the gene SART1 showed a near
doubled frequency in glioblastoma patients, as verified in an independent control cohort by Sanger sequencing. In addition,
we identified SNPs in 20 of 21 GBM associated antigens providing further evidence that genetic variations are significantly
associated with the immunogenicity of antigens.
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Introduction
Glioblastoma (GBM) is the most frequent and most malignant
human primary brain tumor that is characterized by a rapid and
invasive growth pattern, high level of cellular heterogeneity and
poor prognosis [1,2]. Although current standard care for
glioblastoma patients comprises surgical resection followed by
adjuvant radiation therapy and chemotherapy with temozolomide,
most patients die within 2 years after diagnosis [3]. Genetic
hallmarks of glioblastoma are deletion of p16INK4a, mutation of
p53 and PTEN, loss of heterozygosity of chromosome 10q [4], and
gene amplifications including EGFR amplified in 37.5% of GBM
[5]. Additional amplification are frequently found at 12q13-21
including CDK4, KUB3 or CYP27B1. The gene amplification
have been associated with the overall survival of GBM patients [6].
Besides these common features, a manifold of additional
aberrations have been identified for GBM with high-throughput
whole genome and whole transcriptome analysis tools, including
amplicons detected by aCGH data [6–8], aberrant gene
expression profiles detected by microarray screenings [9–11],
deregulated microRNAs [12–14] or single nucleotide polymor-
phisms (SNPs) detected by genome wide association studies
(GWAS) [15,16]. Thus, SNPs in the TERT, RTEL1 and
CDKN2B regions were strongly associated with high-grade glioma
risk. While chromosomal imbalances and aberrant mRNA and
miRNA expression profiles can be identified in tumor cells after
tumor formation, putative SNPs that might be associated with an
increased risk for developing glioblastoma can be identified prior
to tumor formation in DNA from normal samples of a patient.
These genetic predispositions offer essential screening tools to
identify high-risk populations for specific cancers. Furthermore,
the knowledge of such predispositions and of the resulting
molecular changes in cellular processes will further our under-
standing of these tumors and will contribute to a personalized
medicine.
For decades, Sanger sequencing was the only reliable method
available to sequence DNA fragments with high accuracy.
However, the throughput was rather low and sequencing of
several hundreds of genes was very expensive. For genome wide
identification of DNA sequence variations, new sequencing
technologies had to be developed. The three next generation
sequencing (NGS) systems that are available up to date are based
on different principles, including pyrosequencing [17], sequenc-
ing-by-synthesis [18] or sequencing-by-ligation [19]. All three
methods have in common that DNA is fragmented and bound to
adapter sequences that facilitate singularisation and binding of the
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pyrosequencing, second strand DNA is synthesized with incorpo-
rated nucleotides being simultaneously detected using either
fluorescently-labeled nucleotides in the first or the pyrophos-
phate-to-ATP conversion and subsequent luciferase reaction in the
latter case. For sequencing-by-ligation, fluorescently labeled
specific oligonucleotides are hybridized to the immobilized
DNA, scanned and subsequently cleaved to enable a new round
of hybridization.
Searching for novel SNPs and variants in genes associated
with glioblastoma, we combined the HybSelect sequence
capture technology of febit [20], a DNA microarray-based
capture technology that has been shown to work efficiently with
various human cancer-related genes in the past [21], with the
deep sequencing technology of Illumina. We selected 132 GBM-
associated genes on different chromosomes, spanning a total of
2.2 MB and generated about 60.000 capture probes spanning a
region of interest of 504 kb on a customized enrichment chip.
We performed targeted enrichment with genomic DNA isolated
both from peripheral blood leukocytes and tumor tissue from
two different glioblastoma patients. After sequencing, novel
SNPs and variants have been called and the most interesting
SNPs have been verified in independent samples by Sanger
sequencing.
Finally, we analyzed the identified SNPs for an association with
21 autoantigens, suggested triggering a humoral immune response
in glioblastoma patients.
Results
Targeted re-sequencing
To enrich the genomic DNA for the 132 glioma-associated
genes, we applied a microarray based approach as detailed in the
Methods section and previously described [21]. The four enriched
and sequenced samples are denoted as patient A-leuko, patient B-
leuko, patient A-tumor and patient B-tumor. After enrichment of
gene sequences with HybSelect, all samples were sequenced on a
single lane on an Illumina Genome Analyzer II, generating on
average 30.6*10
6 50 bp paired-end reads per lane. After excluding
artifacts as described in Material and Methods, an average of
16.7*10
6 paired-end reads remained. After mapping the data to
the human genome and excluding reads that map to multiple
locations, we obtained on average 3.1*10
6 reads allowing a 308
fold coverage and a target coverage of approximately 87%. We
obtained an up to 844 fold enrichment as compared to a random
sequencing. An example of a plot with an exonic part of the
SART1 gene and a coverage for the four samples is shown in
Figure 1.
Figure 1. Coverage plot for one exonic part of SART1 for the four control samples. X-axis shows the genomic coordinate inside the exon,
y-axis denotes the number of reads covering this position and the four lines correspond to the four genomic samples.
doi:10.1371/journal.pone.0018158.g001
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For an in-depth SNP and Indel analysis, the data was remapped
using NextGENe (Softgenetics, Pennsylvania, USA). Paired-end
reads were mapped against the human genome NCI build 36.1
using NextGENe. The method that is based on hybridization of
DNA sequences to complementary oligonucleotides, allows the
enrichment of DNA sequences of the target genes, but does not
necessarily exclude all sequences similar to the target genes.
Therefore, we detected also sequences of genes other than the
targeted ones. In total we detected 2753 SNPs or Indels in
leukocyte DNA of patient A, 2346 in tumor DNA of patient A,
1527 in leukocyte DNA of patient B, and 2356 in tumor DNA of
patient B (Table 1). Considering the 132 GBM associated target
genes, we detected 581 SNPs or Indels in leukocyte DNA of
patient A, 415 in tumor DNA of patient A, 272 in leukocyte DNA
of patient B, and 516 in tumor DNA of patient B. In total, we
detected 1317 different SNPs in all four samples with 57 SNPs
found in each of the samples, as summarized in the Venn diagram
of Figure 2A. Depending on the sample, between 15 and 26% of
all detected SNPs and between 34 and 64% of the SNPs in the
target genes have already been annotated in the dbSNP.
Summarizing all detected SNPs in all four samples, we detected
6196 different SNPs (1057 annotated in dbSNP), including 1317
that mapped to the 132 target genes and 4879 that mapped to the
remaining 1030 genes. Table S1 provides the complete list of all
detected SNPs in all four samples.
Performing a pairwise overlap of the four data sets we found
more overlaps between the samples of each patient e.g. tumor
versus leukocytes, than between the patients. In detail, we found
19.4% and 25.9% overlap for the comparison of tumor versus
leukocytes of patient A and patient B, respectively. The overlaps
between the blood samples of the two patients were only 18.5%,
and between the tumor samples of the two patients 17.3%
(Table 2).
To identify SNPs that might indicate tumor specific genetic
changes we searched for SNPs that show a different genotype in
the leukocytes as compared to the tumor DNA. We found several
SNPs with a coverage above 50 including SNP rs715930 in the
gene B4GALNT1. For this SNP that is annotated as ‘C’ in the
wild type, we found a heterozygous ‘AC’ status in leukocytes of
patient A, and an ‘A’ allele in the tumor of this patient. This might
either indicate a homozygous ‘AA’ status or potentially a
hemizygous status due to loss of heterozygocity in the tumor.
SNP rs12172263 in gene sequence LOC643266 is annotated as
‘G’ the reference genome. Likewise, we found a heterozygous ‘TG’
status in the leukocytes of patient A and a ‘T’ allele in the tumor of
this patient. Further examples for a heterozygous status in the
leukocytes as compared to a hemizygous or homozygous in the
according tumor were found for the SNP rs1805414 mapping in
PARP1 gene, SNP rs935037 in PAXIP1 gene and SNP rs962976
in MDM1 gene (Table 3).
To further elucidate a disease association of the identified SNPs,
we computed the overlap between the detected SNPs and the 2967
SNPs reported in the genome-wide association study (GWAS)
catalog. We found two SNPs, namely rs6265 that was associated
with smoking behavior [22] and body mass index [23] and
rs6010620 that was related to high-grade glioma [15].
SNP rs660118 that was found homozygous in both blood and
tumor of the two patients, was recently associated with breast
cancer [24]. Together with three other SNPs of the SART1 gene
(here, aligned NGS reads are shown in Figure 2B), SNP rs660118
constitutes a haplotype that was associated with increased risk of
breast cancer. For this haplotype, rs660118 and rs679581
represent the minor alleles (1), and rs754532 and rs735942 the
major alleles (0). We found this ‘‘1100’’ haplotype in both blood
and tumor of the two patients.
Sanger verification and independent replication
For verification purposes we carried out Sanger sequencing of
the exons containing the four SNPs. We confirmed the ‘‘1100’’
haplotype in all four samples. This haplotype has not been
detected with increased frequency in ten blood samples of
glioblastoma patients as compared to ten blood samples of healthy
controls. However, including the two samples originally used for
SNP identification we found an equal distribution of the SNP
rs660118 between glioblastoma patients with homozygous minor
allele (C) status, heterozygous (G/C) status, and homozygous
major allele (G) status, whereas in the healthy controls we found
the wildtype allele in 70% of cases, the rare allele in 10% and the
heterozygous status in 20% of cases. Thus the SNP rs660118 that
is essential for the ‘‘1100’’ haplotype was correlated with
glioblastoma. Sanger Traces are shown in Figure 3A and the
results are summarized in the sequence logo in Figure 3B.
Integrating tumor-associated antigens
Beside the tumor association, we analyzed the identified SNPs
for an association with autoantigens. An association between SNPs
and immunogenicity of autoantigens was previously suggested
[25]. Recently, we reported 21 genes associated with humoral
immune response in glioblastoma patients [26]. We detected single
nucleotide polymorphisms in at least one of the analyzed samples
for 95.2% of these genes (Table S2).
We found five SNPs that were homozygous for alleles that were
different from the reference sequence. These homozygous alleles
were found in the two patients both in blood and tumor.
Specifically, rs4715630 and rs4715631 map within the DST gene,
rs176924 in the KIF5B gene, rs2301263 in the GPI gene, and
rs41427849 in the ZNF594 gene. We also found five SNPs that
were homozygous for the minor alleles in three of the four
samples. Specifically, rs1800606 maps within the APBB1 gene,
rs4283892 and rs4715626 in DST gene, rs10418774 in the
ZNF324 gene and rs4764506 in ING4 gene. In four out of these
Table 1. Overall number of detected SNPs and SNPs detected in target genes.
Sample ID DNA type No. of Overall SNPs [thereof known] No. of SNPs in target genes [thereof known]
patient A leuko 2753 [444] 581 [197]
patient B leuko 1527 [235] 272 [112]
patient A tumor 2346 [613] 415 [265]
patient B tumor 2356 [420] 516 [239]
Number of known SNPs in brackets.
doi:10.1371/journal.pone.0018158.t001
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different from the reference sequence (Table S2). These results
provide further evidence that SNPs are associated with the
immunogenic antigens.
Discussion
For four glioblastoma samples we performed targeted resequen-
cing that is increasingly recognized as valuable screening tool for
an in-depth analysis of genomic regions while avoiding problems
attached to storage and handling of a large collection data that
result from whole genome sequencing. With our approach, we
could not completely avoid detecting sequences of genes other
than the target genes. This might partially be due to sequence
similarities between target and non-target genes, e.g. in gene
families. An additional limitation is the small number of samples
sequenced. However, even this limited number of samples
indicates that additional important SNPs are likely to be found
in a larger group of patients.
We detected several hundred SNPs mapping to 132 genes in the
glioblastoma samples. For several SNPs we found a heterozygous
situation in the leukocyte DNA and a homozygous or hemizygous
situation in the tumor DNA of the same patient. Unfortunately
cytogenetic information on these specific tumor tissues was not
available. In general, glioblastoma are genetically highly hetero-
geneous with multiple chromosomal aberrations including loss of
heterozygosity. Losses of chromosomal material occur frequently
for chromosomes 6, 9p, 11p, 19q, 22q [27]. Losses of chromosome
10 are associated with primary glioblastoma that occur without
any low-grade precursor lesion [2]. Probably, the differences that
we found for several SNPs between leukocyte and tumor DNA are
due to loss of heterozygosity in the glioblastoma samples.
For several of the identified SNPs there is evidence for an
association with cancer. The SNP rs660118 maps within the SART1
(squamous cell carcinoma antigen recognized by T cells) gene that is
also known as tumor-rejection antigen in brain tumors [28] and in a
range of other tumors including hepatocellular carcinoma [29],
colorectal cancer [30], renal cell carcinoma [31], and osteosarcoma
[32]. Amplification and overexpression of SART1 occursin head and
neck squamous cell carcinoma (HNSCC) [33]. Functionally, SART1
is required for maintenance of normal mitotic processes with either
overexpression or depletion causing mitotic defects including cell
cycle arrest and apoptosis [24,34]. SNPs rs660118 and SNP rs679581
the latter of which also map within the SART1 gene are associated
with increased breast cancer risk as shown by the analysis of 798
breast cancer patients and 843 controls [24]. In our study we
identified and verified a minor allele of SNP rs660118 in a cohort of
glioblastoma and control samples.
Based on the reported evidence that SART1 is a tumor antigen
we reviewed our own data on antigens that are reactive with tumor
sera [26]. Summarizing the data of more than 400 cases including
cancer sera, sera of patients with non-cancer diseases and healthy
controls, we found an overall 10% increase of autoantibody
response to SART1 in cancer sera as compared to normal controls
and non-cancer diseases. It is conceivable that the SNP rs660118
that maps within the exonic sequence of SART1 plays a role in the
immunogenicity of this gene. The hypothesis that SNPs are
associated with immunogenic antigens was first proposed by
Stadler et al. [25]. This idea is also supported by our finding of
SNPs in genes previously associated with humoral immune
response in glioma patients [26,35].
In summary, our results provide evidence that targeted
resequencing is well suited to detect single nucleotide polymor-
phisms that may correlate with disease risks. The approach may be
especially applicable in personalized medicine to assess the
relevant genotype of a patient at reasonable cost. Moreover,
combined with multiplexing and customized SNP array design,
targeted resequencing also offers the option to validate SNPs
detected by GWAS studies in independent sample cohorts.
Materials and Methods
Study design
The major aim of our study was the identification of novel SNPs
in genes already associated with glioblastoma using a combination
of specific target selection and next generation sequencing. We
selected a total of 132 genes including 21 genes associated with an
anti-tumor humoral immune response in glioma [26], 55 genes
Table 2. Distribution of detected SNPs among the samples.
sample 1 sample 2 only in sample 1 [n] only in sample 2 [n] in both samples [n] Overlap [%]
patient A leuko patient A tumor 1924 1517 829 19.4
patient B leuko patient B tumor 729 1558 798 25.9
patient A leuko patient B leuko 2086 860 667 18.5
patient A tumor patient B tumor 1654 1664 692 17.3
patient A leuko patient B tumor 2044 1647 709 16.1
patient B leuko patient A tumor 920 1739 607 18.6
doi:10.1371/journal.pone.0018158.t002
Figure 2. Venn diagram of detected SNPs in the 132 targeted
genes in the four samples.
doi:10.1371/journal.pone.0018158.g002
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tumors [35–37], and 53 genes shown to be amplified or abnormally
expressed in glioblastoma. (For specific details on the selection
criteria ofspecificgenes,seeTable S1).Inaddtionweincluded three
genes that were randomly selected for control purposes. Oligonu-
cleotidescomplementarytothe exonicregionsofthe132geneswere
synthesized on a biochip array as detailed below. This array was
used to enrich the target sequences of four genomic DNA samples
including tumor and leukocytes of two glioblastoma patients. In
detail, genomic DNA was fragmented and adaptors were ligated.
The adaptor-DNA-fragments were hybridized to a first array. After
stringently washing, bound DNA, which is enriched for the target
gene DNA, was eluted as details below. After amplification of the
eluted DNA using the adaptor sequence, a second round of
enrichment was performed using a second array and the eluted
DNA was sequenced. The resulting reads were mapped to the
human genome and SNPs were called as detailed below. For
analysis we focused on SNPs that were called in multiple samples,
that showed differences between leukocytes and tumor of the same
patient, and that were called in genes associated with a humoral
immune response in brain tumors.
Microarray Design and Synthesis
Light-activated in situ oligonucleotide synthesis on Geniom
Biochips was performed as described previously [21]. One Biochip
holds eight individual, microfluidic channels each containing an
array of 15,624 individual DNA probe features.
For the glioblastoma chip, gene sequences were downloaded
from NCBI built 36.1 and 56,184 50mer probes were tiled across
the target genes with an average density of 11 bp targeting sense
and antisense strand in an alternating manner. For biochip
synthesis, they were distributed over 4 arrays. Each exon was
covered by at least20 probes, i.e. small exonsweretiled more dense.
The full region of interest was 2.2 Mb corresponding to a core
target region containing high complexity sequences of 504 Kb.
DNA sample preparation
5 mg genomic DNA sample were dissolved in 80 ml of water and
fragmented for 30 min by sonication at medium intensity
(Bioruptor, Diagenode, Lie ´ge, Belgium). 5 ml were controlled on
a 2% agarose gel for the correct fragment size distribution.
Preparation of the paired end adaptor-ligated gDNA library ready
for sequencing on an Illumina/Solexa Genome Analyzer II
(Illumina, San Diego, CA, USA) was performed according to the
manufactures standard protocol. The size fraction of 300–500 bp
for gDNA was excised from an agarose gel after the adaptor
ligation step and the sample was analyzed by Bioanalyzer 2100
analysis (Agilent), quantified by Nanodrop 1000 UV measurement
(Thermo Scientific, Waltham, MA, USA) and stored in EB buffer
at 220uC until use.
Table 3. SNPs with different genotype in tumor and leukocytes of the same patient.
patient gene position chromosome reference sample coverage A C G T genotype dbSNP Hgvs*
A B4GALNT1 56310248 12 C Leu 154 30;70 0;54 0;0 0;0 AC rs715930 c.[666C.A]
+[=]
Tu 123 61;48 7;6 0;0 0;0 AA rs715930 c.[666C.A]+
[666C.A]
LOC643266 47216571 22 G Leu 96 27;0 0;0 69;0 0;0 GA rs12172263 c.[820+466G
.A]+[=]
Tu 115 115;0 0;0 0;0 0;0 AA rs12172263 c.[820+466G
.A]+[820+
466G.A]
LOC644033 4412 8 G Leu 127 0;0 0;0 21;24 42;40 TG na c.[26–95G.
T]+[=]
Tu 74 0;0 0;0 7;4 31;32 TT na c.[26–95G.
T]+[26–
95G.T]
PARP1 224639987 1 A Leu 102 23;24 0;0 0;55 0;0 GA rs1805414 c.[852A.G]
+[=]
Tu 61 4;4 0;0 11;42 0;0 GG rs1805414 c.[852A.G]
+[852A.G]
B CTDSP2 56503706 12 C Leu 118 0;0 51;16 0;0 11;40 CT na c.[762C.T]
+[=]
Tu 3580 3;0 64;82 4;1 1235;2190 TT na c.[762C.T]
+[762C.T]
PAXIP1 154391302 7 A Leu 114 13;16 0;0 26;59 0;0 GA rs935037 c.[1440A.G]
+[=]
Tu 286 0;0 0;0 64;222 0;0 GG rs935037 c.[1440A.G]
+[1440A.G]
MDM1 67006894 12 G Leu 52 27;10 0;0 8;7 0;0 AG rs962976 c.[308G.A]
+[=]
Tu 99 74;8 0;0 13;4 0;0 AA rs962976 c.[308G.A]
+[308G.A]
*HGVC=Human Genome Variation Society.
Supporting Information Legends.
doi:10.1371/journal.pone.0018158.t003
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F o rfo u ra r r a y s ,6mg adaptor-ligated gDNA library were dried in a
speed-vac together with 64 mL febit hybridization booster mix. The
dried pellet was dissolved in 100 ml febit Hybmix-4, heated to 95uC
for 5 min and placed on ice. The sample mixture was split into four
equal parts, placed into the sample loading station of the Geniom RT
Analyzer and automatically injected into the microfluidic channels of
the biochip. Sample was denatured within the biochip at 80uCf o r
10 min and hybridized for 16 h at 42uC with active movement of the
sample. After hybridization, each array was automatically washed
with 66SSPE at room temperature and 0.56SSPE at 45uC. Each
array was subsequently washed with SSPE-based febit stringent wash
buffers 1 and 2 at room temperature. All protocol steps were carried
out in a completely automated fashion by the Geniom RT Analyzer
instrument without manual interference.
For elution of the enriched samples, arrays were filled with
15 mL of 90% formamide in water each and incubated at 70uC for
30 min. Solution was manually transferred into an reaction tube
and dried by vacuum centrifugation in a Speed-Vac at 65uC. After
an amplification step according to the Illumina library preparation
procedure using primers PE Adapter 1.1 and PE Adapter 2.1 for
30 cycles, the sample was treated like the original library and
subjected to a second round of enrichment under the same
conditions as before, using a newly synthesized biochip.
Eluted samples were subjected to 10 cycles of PCR according to
the conditions described in the Illumina library preparation kit
using paired end primers and purified by a Qiagen MinElute PCR
purification (Qiagen, Hilden, Germany). Quantification of samples
was done by the Quant-It Picogreen assay (Invitrogen, Carlsbad,
CA, USA) using the Nanodrop 3300 instrument (Thermo
Scientific, Wilmington, DE, USA).
Paired-End Sequencing
Paired-end sequencing on an Illumina Genome Analyzer II
was carried out as described in the manufacturer’s manual by
Prognosys Inc (La Jolla, CA, USA).
Data analysis & SNP Verification
Paired-end reads (50 bp in length) were first filtered by
removing reads with ambiguous nucleotide calls (3 or more N).
Reads from File 1 and File 2 of the two paired end sequences were
aligned with target genes by using razerS, which is part of SeqAn,
an open source C++ library of efficient algorithms and data
structures for the analysis of biological sequences. The parameters
used were ‘‘-gn 1 -f -r -i 94 -rr 100 -m 10’’ which allows up to 3
mismatches. The output alignment files were matched for each
pair of reads: the two reads were mapped to opposite strands and
in correct orientation and the length between the two reads was
within 100–500 bp. The fold coverage for each base within the
probe regions was calculated for unique reads.
Initial data analysis was carried out with Eland. Re-mapping of
the raw reads files was additionally done with NextGENe. The
default parameters were used for format conversion and the
subsequent alignment, allowing up to two mismatches. Called
SNPs with coverage of higher 50 have are considered as SNPs with
high confidence, SNPs with coverage of smaller 10 reads have
been removed from the consideration.
Subsequent data analysis, including coverage plots, has been
carried out using the freely available R [38] and perl software.
Four SNPs were exemplarily verified with Sanger sequencing.
We amplified exon 12 of the SART1 gene containing the four
SNPs described by Olson et al. [25] and carried out Sanger
sequencing using the following primers for amplification and
sequencing: forward1-59-ACTGCGGGGACGGGGT-39, rever-
se1-59-CTTCTCGCCACTGTCTCGCA-39 (rs660118), respecti-
vely: forward2-59-TCTCTGCAGGAACACCATCA-39, reverse
2-59-CGTCCCATCCTTCACACCT-39 (rs679581, rs754532 and
rs735942). Traces have been evaluated with the freely available
tool ‘‘Mac Sequence View’’ and alignments have been computed
using clustalW.
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detected SNPs in all four samples.
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